uploads/2017/02/part-5-1.png

What Are Analysts’ Recommendations for Chemours?

By

Updated

Analysts’ recommendations

Before the 4Q16 earnings release, eight brokerage firms were actively tracking Chemours (CC) stock. About 25.0% of the analysts recommended a “buy” for the stock, while 63.0% of them recommended a “hold.” About 12.0% recommended a “sell.”

Article continues below advertisement

Recommendations after its 4Q16 earnings

Analysts’ recommendations changed after Chemours’ 4Q16 earnings. As of February 16, 2017, eight brokerage firms were actively tracking Chemours stock. About 38.0% of the analysts recommended a “buy” for the stock, while 50.0% of them recommended a “hold.” About 12.0% recommended a “sell.” Analysts recommended a 12-month target price for Chemours at $29.57. It indicates a potential return of -7.3% compared to the closing price of $31.9 as of February 16, 2017.

Recommendations and targets

Below are some recommended target prices for Chemours from some well-known brokerage firms:

  • On February 16, 2017, Goldman Sachs (GS) rated Chemours as a “buy” with a target price of $42. It implies a 12-month return of 31.70% based on the closing price of $31.90 on February 16, 2017.
  • On February 14, 2017, Jefferies provided Chemours with a target price of $35. It implies a 12-month return of 9.7% based on the closing price of $31.90 on February 16, 2017.
  • On February 14, 2017, Citigroup (C) provided Chemours with a target price of $34. It implies a 12-month return of 6.6% based on the closing price of $31.90 on February 16, 2017.

You can indirectly hold Chemours by investing in the PowerShares DWA Basic Materials Momentum ETF (PYZ). PYZ invested 4.5% of its holdings in Chemours as of February 16, 2017. The fund’s top holdings include Cliffs Natural Resources (CLF) and Avery Dennison (AVY). They have weights of 4.8% and 3.6%, respectively.

Advertisement

More From Market Realist